AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Sandoz Group AG
Video analysis: SDZNY
All videosNo video analysis for this stock yet. Request one from our team.
News: SDZNY
Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript
Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth
Sandoz aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its focus from generics to biosimilars.
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million The collaboration further expands the parties' 2025 oncology biosimilars partnership SHANGHAI, Aug. 17, 2026 /PRNewswire/ -- On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech
Swiss generic drugmaker Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drugmaker said on Monday.
Sandoz Group AG (SDZNY) Q2 2026 Earnings Call Transcript
Sandoz Group AG (SDZNY) Q2 2026 Earnings Call Transcript
Sandoz Shares Climb After Biosimilar Sales Drive Growth
Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a return to growth in generics.
Similar companies
-
Bayer AG
BAYRY
·
Other OTC
Compare
-
Otsuka Holdings Co., Ltd.
OTSKY
·
Other OTC
Compare
-
JD Health International Inc.
JDHIF
·
Other OTC
Compare
-
Koninklijke Philips N.V.
RYLPF
·
Other OTC
Compare
-
Fresenius SE & Co. KGaA
FSNUF
·
Other OTC
Compare
-
Teva Pharmaceutical Industries Limited
TEVJF
·
Other OTC
Compare